Taysha Gene Therapies TSHA reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Taysha Gene Therapies beat estimated earnings by 936.0%, reporting an EPS of $0.92 versus an estimate of $-0.11.
Revenue was up $1.10 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.76 which was followed by a 26.0% increase in the share price the next day.
Here's a look at Taysha Gene Therapies's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.31 | -0.35 | -0.33 |
| EPS Actual | -0.93 | -0.38 | -0.28 | -0.34 |
| Revenue Estimate | 1.40M | 2.00M | 70K | 8.18M |
| Revenue Actual | 4.75M | 2.40M | 4.71M | 2.50M |
To track all earnings releases for Taysha Gene Therapies visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
